W. Zavadoski

发表

Modeling the Mechanism of Action of a DGAT1 Inhibitor Using a Causal Reasoning Platform

Nigel Greene, Daniel Ziemek, Ranjit Randhawa, 2011, PloS one.

Constitutively Elevated Blood Serotonin Is Associated with Bone Loss and Type 2 Diabetes in Rats

S. Vukicevic, V. Paralkar, J. Brkljačić, 2016, PloS one.

Discovery of spirocyclic proline tryptophan hydroxylase-1 inhibitors.

V. Paralkar, D. Goldberg, W. Zavadoski, 2016, Bioorganic & medicinal chemistry letters.

Pharmacological inhibition to examine the role of DGAT1 in dietary lipid absorption in rodents and humans.

S. Watkins, Tara B. Manion, Dawn Mather, 2013, American journal of physiology. Gastrointestinal and liver physiology.

Nitric oxide increases cyclic GMP levels, AMP-activated protein kinase (AMPK)α1-specific activity and glucose transport in human skeletal muscle

A. Deshmukh, H. Koistinen, J. Zierath, 2010, Diabetologia.

Discovery of acyl guanidine tryptophan hydroxylase-1 inhibitors.

V. Paralkar, D. Goldberg, W. Zavadoski, 2016, Bioorganic & Medicinal Chemistry Letters.

Insulin-sensitive regulation of glucose transport and GLUT4 translocation in skeletal muscle of GLUT1 transgenic mice.

G. Etgen, W. Zavadoski, E. M. Gibbs, 1999, The Biochemical journal.

Optimization of spirocyclic proline tryptophan hydroxylase-1 inhibitors.

V. Paralkar, D. Goldberg, W. Zavadoski, 2017, Bioorganic & medicinal chemistry letters.

The design and synthesis of a potent glucagon receptor antagonist with favorable physicochemical and pharmacokinetic properties as a candidate for the treatment of type 2 diabetes mellitus.

J. Treadway, J. Pfefferkorn, W. Zavadoski, 2013, Bioorganic & medicinal chemistry letters.

The PPAR-γ Agonist, Darglitazone, Restores Acute Inflammatory Responses to Cerebral Hypoxia–Ischemia in the Diabetic ob/ob Mouse

S. Vannucci, I. Simpson, R. Kumari, 2010, Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism.

A human APOC3 missense variant and monoclonal antibody accelerate apoC-III clearance and lower triglyceride-rich lipoprotein levels

Ildikó V. Tóth, D. Rader, S. Kathiresan, 2017, Nature Medicine.

Discovery of PF-04620110, a Potent, Selective, and Orally Bioavailable Inhibitor of DGAT-1.

Eliot Sugarman, Angel Guzman-Perez, G. S. Walker, 2011, ACS medicinal chemistry letters.

Pigment surface treatments : a bench chemist's guide

W. Zavadoski, E. Faulkner, 1994 .

Discovery of (S)-6-(3-cyclopentyl-2-(4-(trifluoromethyl)-1H-imidazol-1-yl)propanamido)nicotinic acid as a hepatoselective glucokinase activator clinical candidate for treating type 2 diabetes mellitus.

Jing Chen, David B Duignan, Robert Aiello, 2012, Journal of medicinal chemistry.

Acute Effects of Atypical Antipsychotics on Whole-Body Insulin Resistance in Rats: Implications for Adverse Metabolic Effects

K. Houseknecht, W. Zavadoski, E. M. Gibbs, 2007, Neuropsychopharmacology.

Polyomic profiling reveals significant hepatic metabolic alterations in glucagon-receptor (GCGR) knockout mice: implications on anti-glucagon therapies for diabetes

J. Treadway, J. Baker, M. McDowell, 2011, BMC Genomics.

5-Chloroindoloyl glycine amide inhibitors of glycogen phosphorylase: synthesis, in vitro, in vivo, and X-ray crystallographic characterization.

V. L. Rath, S. Wright, D. Hageman, 2005, Bioorganic & medicinal chemistry letters.

Defining the key pharmacophore elements of PF-04620110: discovery of a potent, orally-active, neutral DGAT-1 inhibitor.

Angel Guzman-Perez, Dawn Mather, W. Zavadoski, 2013, Bioorganic & medicinal chemistry.

The discovery of potent, selective, and orally bioavailable PDE9 inhibitors as potential hypoglycemic agents.

W. Zavadoski, A. Bell, Dianna E. Moore, 2009, Bioorganic & medicinal chemistry letters.

A stapled lipopeptide platform for preventing and treating highly pathogenic viruses of pandemic potential

Marina Godes, L. Walensky, W. Zavadoski, 2024, Nature communications.